JSB Market Research: Asthma Therapeutics Market to 2019
GBI Research, a leading business intelligence provider, has released its latest research report, "Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth". The asthma market is forecast to grow marginally over the forecast period across the leading eight developed nations, from $16.6 billion in 2012 to a projected value of $21.6 billion in 2019.
GBI Research, a leading business intelligence provider, has released its latest research report, "Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth". The asthma market is forecast to grow marginally over the forecast period across the leading eight developed nations, from $16.6 billion in 2012 to a projected value of $21.6 billion in 2019.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
4. <strong>Asthma</strong> Pipeline<br />
4.1. Overview<br />
4.2. Mechanisms of Action in the Pipeline<br />
4.3. Clinical Trials<br />
4.3.1. Failure Rate<br />
4.3.2. Clinical Trial Duration<br />
4.3.3. Clinical Trial Size<br />
4.3.4. Comparative Clinical Trial Metrics Analysis<br />
4.4. Promising Pipeline Molecules<br />
4.4.1. Reslizumab - Teva Pharmaceutical ltd<br />
4.4.2. Mepolizumab - GlaxoSmithKline<br />
4.4.3. Lebrikizumab - Roche/Genentech<br />
4.4.4. Veramyst - GlaxoSmithKline<br />
4.4.5. Andolast - Rottapharm Madaus<br />
4.4.6. Spiriva (Tiotropium Bromide) - Boehringer Ingelheim<br />
4.5. Heat Map of Safety and Efficacy for Pipeline and <strong>Market</strong>ed Products<br />
5. <strong>Market</strong> Forecast <strong>to</strong> <strong>2019</strong><br />
5.1. Geographical <strong>Market</strong>s<br />
5.1.1. Global <strong>Market</strong><br />
5.1.2. North America<br />
5.1.3. Top Five Countries of Europe<br />
5.1.4. Japan<br />
5.2. Drivers and Barriers for the <strong>Asthma</strong> <strong>Therapeutics</strong> <strong>Market</strong><br />
5.2.1. Drivers<br />
5.2.2. Barriers<br />
6. Strategic Consolidations<br />
6.1. Major Licensing Deals<br />
6.2. Major Co-development Deals<br />
7. Appendix<br />
7.1. All Pipeline Drugs by Phase<br />
7.1.1. Discovery<br />
7.1.2. Preclinical<br />
7.1.3. Phase I<br />
7.1.4. Phase II<br />
7.1.5. Phase III<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Change language